Publications

Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with a diagnosis of pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (1998). by Lewis MT, Gales AC, Sader HS, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (1): 63-74

Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): Case reports from the SENTRY Antimicrobial Surveillance Program. by Kugler KC, Denys GA, Wilson ML, and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (4): 269-272

Anti-gonococcal activity of gemifloxacin against fluoroquinolone- resistant strains and a comparison of agar dilution and Etest methods. by Jones RN, Deshpande LM, Erwin ME, Barrett MS and Beach ML published in J. Antimicrob. Chemother. 2000; 45 (Suppl 1): 67-70

In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997- 1998. by Jones RN, Jenkins SG, Hoban DJ, Pfaller MA and Ramphal R published in Int. J. Antimicrob. Agents. 2000; 15 (2): 111-118

In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. by Jones RN, Jenkins SG, Hoban DJ, Pfaller MA and Ramphal R published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 93-98

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). by Jones RN, Croco MA, Kugler KC, Pfaller MA and Beach ML published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 115-125

Cefditoren activity against nearly 1,000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. by Jones RN, Biedenbach DJ and Johnson DM published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 143-146

Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group. by Jones RN and Erwin ME published in Diagn. Microbiol. Infect. Dis. 2000; 37 (3): 195-201

Evaluation of gemifloxacin (SB-265805, LB20304a): In vitro activity against over 6,000 Gram-positive pathogens from diverse geographic areas. by Jones RN, Pfaller MA and Erwin ME published in Int. J. Antimicrob. Agents 2000; 15 (3): 227-230

Perspectives on the development of new antimicrobial agents for resistant Gram-positive pathogens. by Jones RN published in Braz. J. Infect. Dis. 2000; 4 (1): 1-8

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY Antimicrobial Surveillance Program. by Jones RN and Pfaller MA. published in Clin. Infect. Dis. 2000; 31 (Suppl 2): S16-23

Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection. by Jones RN published in J. Antimicrob. Chemother. 2000; 46 (Suppl T2): 1-8

Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: Significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999). by Jones RN and Pfaller MA published in J. Clin. Microbiol. 2000; 38 (11): 4298-4299

Potencies of newer fluoroquinolones against viridans group streptococci isolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): Beyond Canada! by Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2000; 44 (10): 2922-2923

Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. by Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 99-105

Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: Report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). by Gales AC, Jones RN, Gordon KA, Sader HS, Wilke WW, Beach ML, Pfaller MA and Doern GV published in J. Antimicrob. Chemother. 2000; 45 (3): 295-303

Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 1997-98. SENTRY Study Group. by Gales AC, Jones RN, Pfaller MA, Gordon KA and Sader HS published in Int. J. Infect. Dis. 2000; 4 (2): 75-84

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. by Gales AC and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (1): 19-36

Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. by Gales AC, Gordon KA, Wilke WW, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (1): 61-64

Oxazolidinones: A review. by Diekema DI and Jones RN published in Drugs 2000; 59 (1): 7-16

Microbiology of infections in the coronary care unit. by Diekema DJ and Jones RN published in Antibiotics for Clinicians2000; 4 (Suppl 1): 5-10

Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. by Diekema DJ, Pfaller MA, Jones RN, Doern GV, Kugler KC, Beach ML and Sader HS published in Int. J. Antimicrob. Agents 2000; 13 (4): 257-271

Genetic relatedness of multidrug-resistant, methicillin (oxacillin)- resistant Staphylococcus aureus bloodstream isolates from SENTRY Antimicrobial Resistance Surveillance centers worldwide, 1998. by Diekema DJ, Pfaller MA, Turnidge J, Verhoef J, Bell J, Fluit AC, Doern GV and Jones RN published in Microb. Drug Resist. 2000; 6 (3): 213-221

Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2,000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999). by Deshpande LM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 139-142

In vitro activity of ceftiofur tested against clinical isolates of Escherichia coli and Klebsiella pneumoniae including extended spectrum β-lactamase producing strains. by Deshpande L, Pfaller MA and Jones RN published in Int. J. Antimicrob. Agents 2000; 15 (4): 271-275

Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. by Burns JL, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z, Marshall SA and Jones RN published in J. Clin. Microbiol. 2000; 38 (5): 1818-1822

Fluoroquinolone-resistant Haemophilus influenzae: Frequency of occurrence and analysis of confirmed strains in the SENTRY Antimicrobial Surveillance Program (North and Latin America). by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (4): 255-259

A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. by Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ and Ballow CH published in Diagn. Microbiol. Infect. Dis. 2000; 36 (3): 145-158

Group B streptococci causing neonatal bloodstream infection: Antimicrobial susceptibility and serotyping results from SENTRY centers in the western hemisphere. by Andrews JI, Diekema DJ, Hunter SK, Rhomberg PR, Pfaller MA, Jones RN and Doern GV published in Am. J. Obstet. Gynecol. 2000; 183 (4): 859-862

In vitro activity of gatifloxacin tested against anaerobic bacteria by reference agar dilution and Etest methods. by Jones RN, Barrett MS and Pfaller MA published in Clin. Microbiol. Infect. 1999; 5 (9): 577-579

Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: Results from the SENTRY Antimicrobial Surveillance Program (1997). by Jones RN, Winokur PL, Pfaller MA, Doern GV and Barrett T published in Clin. Microbiol. Infect. 1999; 5 (8): 478-487

Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines. by Johnson DM, Jones RN and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1999; 33 (2): 87-91

In vitro evaluation of broad-spectrum β-lactams in the Philippines medical centers: Role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group. by Johnson DM, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 291-297

Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates. by Hayward CL, Erwin ME, Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 34 (2): 99-102

Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group. by Erwin ME and Jones RN published in J. Clin. Microbiol. 1999; 37 (1): 279-280

Nosocomial bloodstream infections in United States hospitals: A three- year analysis. by Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN and Wenzel RP published in Clin. Infect. Dis. 1999; 29 (2): 239-244

Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). by Doern GV, Jones RN, Pfaller MA and Kugler K published in Antimicrob. Agents Chemother. 1999; 43 (2): 385-389

Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: A report from the College of American Pathologists Microbiology Proficiency Survey Program. by Doern GV, Brueggemann AB, Pfaller MA and Jones RN published in Arch. Pathol. Lab. Med. 1999; 123 (4): 285-289

Bacterial pathogens isolated from patients with skin and soft tissue infections: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). by Doern GV, Jones RN, Pfaller MA, Kugler KC and Beach ML published in Diagn. Microbiol. Infect. Dis. 1999; 34 (1): 65-72

Comparison of activities of broad-spectrum β-lactam compounds against 1,128 Gram-positive cocci recently isolated in cancer treatment centers. by Diekema DJ, Coffman SL, Marshall SA, Beach ML, Rolston KV and Jones RN published in Antimicrob. Agents Chemother. 1999; 43 (4): 940-943

In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. by Diekema DJ, Pfaller MA, Messer SA, Houston A, Hollis RJ, Doern GV and Jones RN published in Antimicrob. Agents Chemother. 1999; 43 (9): 2236-2239

Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organisms isolated at 10 cancer treatment centers. by Diekema DJ, Jones RN and Rolston KV published in Diagn. Microbiol. Infect. Dis. 1999; 34 (1): 37-43

Survey of bloodstream infections due to Gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. by Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC, Sader HS, Kugler K, and Beach M published in Clin. Infect. Dis. 1999; 29 (3): 595-607

Comparative activity of clinafloxacin and nine other compounds tested against 2,000 contemporary clinical isolates from patients in United States hospitals. by Deshpande LM, Diekema DJ, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 81-88

Colony morphology of Candida spp. as a guide to species identification. by Buschelman B, Jones RN, Pfaller MA, Koontz FP and Doern GV published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 89-91

Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results. by Biedenbach DJ, Jones RN, Lewis MT, Croco MA, and Barrett MS published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 275-282

Accuracy of cefepime antimicrobial susceptibility testing results for Pseudomonas aeruginosa tested on the MicroScan WalkAway System. by Biedenbach DJ, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 305-307

Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and Etest methods. by Biedenbach DJ, Croco MA, Barrett TJ and Jones RN published in Eur. J. Clin. Microbiol. Infect. Dis. 1999; 18 (6): 428-431

In vitro evaluation of cefepime and other broad-spectrum β-lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group. by Biedenbach DJ, Lewis MT and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 277-283

In vitro evaluation of cefepime and other broad-spectrum β-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. by Biedenbach DJ, Johnson DM and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 299-305